Similar articles for PMID: 30692558

Year	Number of Results
2000	1
2002	1
2004	1
2006	1
2007	1
2008	7
2009	3
2010	3
2011	5
2012	8
2013	6
2014	9
2015	8
2016	4
2017	5
2018	4
2019	5
2020	10
2021	12
2022	10
2023	4
2024	0

1

Effects of Dihydroartemisinin-Piperaquine Phosphate and Artemether-Lumefantrine on QTc Interval Prolongation.

Funck-Brentano C, Bacchieri A, Valentini G, Pace S, Tommasini S, Voiriot P, Ubben D, Duparc S, Evene E, Felices M, Corsi M. Funck-Brentano C, et al. Sci Rep. 2019 Jan 28;9(1):777. doi: 10.1038/s41598-018-37112-6. Sci Rep. 2019. PMID: 30692558 Free PMC article.

2

Piperaquine Pharmacokinetic and Pharmacodynamic Profiles in Healthy Volunteers of Papua New Guinea after Administration of Three-Monthly Doses of Dihydroartemisinin-Piperaquine.

Millat-Martínez P, Salman S, Moore BR, Baro B, Page-Sharp M, Batty KT, Robinson LJ, Pomat W, Karunajeewa H, Laman M, Manning L, Mitjà O, Bassat Q. Millat-Martínez P, et al. Antimicrob Agents Chemother. 2022 Aug 16;66(8):e0018522. doi: 10.1128/aac.00185-22. Epub 2022 Jul 6. Antimicrob Agents Chemother. 2022. PMID: 35862743 Free PMC article.

3

Evaluation of the QT effect of a combination of piperaquine and a novel anti-malarial drug candidate OZ439, for the treatment of uncomplicated malaria.

Darpo B, Ferber G, Siegl P, Laurijssens B, Macintyre F, Toovey S, Duparc S. Darpo B, et al. Br J Clin Pharmacol. 2015 Oct;80(4):706-15. doi: 10.1111/bcp.12680. Epub 2015 Jul 14. Br J Clin Pharmacol. 2015. PMID: 25966781 Free PMC article. Clinical Trial.

4

Electrocardiographic Safety of Repeated Monthly Dihydroartemisinin-Piperaquine as a Candidate for Mass Drug Administration.

Millat-Martínez P, Ila R, Laman M, Robinson L, Karunajeewa H, Abel H, Pulai K, Sanz S, Manning L, Moore B, Bassat Q, Mitjà O. Millat-Martínez P, et al. Antimicrob Agents Chemother. 2018 Nov 26;62(12):e01153-18. doi: 10.1128/AAC.01153-18. Print 2018 Dec. Antimicrob Agents Chemother. 2018. PMID: 30249696 Free PMC article.

5

Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial.

Bassat Q, Mulenga M, Tinto H, Piola P, Borrmann S, Menéndez C, Nambozi M, Valéa I, Nabasumba C, Sasi P, Bacchieri A, Corsi M, Ubben D, Talisuna A, D'Alessandro U. Bassat Q, et al. PLoS One. 2009 Nov 17;4(11):e7871. doi: 10.1371/journal.pone.0007871. PLoS One. 2009. PMID: 19936217 Free PMC article. Clinical Trial.

6

Ipragliflozin does not prolong QTc interval in healthy male and female subjects: a phase I study.

Zhang W, Smulders R, Abeyratne A, Dietz A, Krauwinkel W, Kadokura T, Keirns J. Zhang W, et al. Clin Ther. 2013 Aug;35(8):1150-1161.e3. doi: 10.1016/j.clinthera.2013.06.009. Epub 2013 Aug 2. Clin Ther. 2013. PMID: 23910665 Clinical Trial.

7

Safety and efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children.

Nambozi M, Van Geertruyden JP, Hachizovu S, Chaponda M, Mukwamataba D, Mulenga M, Ubben D, D'Alessandro U. Nambozi M, et al. Malar J. 2011 Feb 28;10:50. doi: 10.1186/1475-2875-10-50. Malar J. 2011. PMID: 21352609 Free PMC article. Clinical Trial.

8

Absence of QTc Prolongation with Sodium N-(8-[2-Hydroxybenzoyl] Amino) Caprylate (SNAC), an Absorption Enhancer Co-Formulated with the GLP-1 Analogue Semaglutide for Oral Administration.

Granhall C, Bækdal TA, Breitschaft A, Søndergaard FL, Anderson TW, Thomsen M. Granhall C, et al. Diabetes Ther. 2021 Sep;12(9):2599-2610. doi: 10.1007/s13300-021-01106-x. Epub 2021 Jul 28. Diabetes Ther. 2021. PMID: 34319564 Free PMC article.

9

Pharmacokinetic Interactions between Tafenoquine and Dihydroartemisinin-Piperaquine or Artemether-Lumefantrine in Healthy Adult Subjects.

Green JA, Mohamed K, Goyal N, Bouhired S, Hussaini A, Jones SW, Koh GC, Kostov I, Taylor M, Wolstenholm A, Duparc S. Green JA, et al. Antimicrob Agents Chemother. 2016 Nov 21;60(12):7321-7332. doi: 10.1128/AAC.01588-16. Print 2016 Dec. Antimicrob Agents Chemother. 2016. PMID: 27697758 Free PMC article. Clinical Trial.

10

Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial.

West African Network for Clinical Trials of Antimalarial Drugs (WANECAM). West African Network for Clinical Trials of Antimalarial Drugs (WANECAM). Lancet. 2018 Apr 7;391(10128):1378-1390. doi: 10.1016/S0140-6736(18)30291-5. Epub 2018 Mar 29. Lancet. 2018. PMID: 29606364 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

101 results

Results by year